Investment Rating - The investment rating for Kuaishou is "Buy" and is maintained [7] Core Insights - Kuaishou's Q3 2025 revenue reached 35.6 billion CNY, representing a year-on-year growth of 14%. The Non-GAAP net profit was 5 billion CNY, up 26% year-on-year. Domestic business operating profit was 5.4 billion CNY, a significant increase of 54% year-on-year, while overseas business incurred an operating loss of 200 million CNY [2][4] Revenue Breakdown - Kuaishou's Q3 2025 online marketing service revenue was 20.1 billion CNY, growing 14% year-on-year, contributing 56.5% to total revenue. The growth was driven by AI-enabled advertising, with ad load and eCPM both improving, leading to a 4-5% increase in domestic advertising revenue. The company also saw a 3% increase in live streaming revenue, totaling 9.6 billion CNY, contributing 26.9% to total revenue. Other services, including e-commerce, generated 5.9 billion CNY, a 41% increase year-on-year, contributing 16.6% to total revenue [8] User Engagement - Kuaishou's content ecosystem continues to thrive, with average daily active users (DAU) reaching 416 million, a 2.1% year-on-year increase, and average monthly active users (MAU) reaching 731 million, up 2.4% year-on-year [8] Profitability Metrics - Kuaishou achieved a gross margin of 54.7% in Q3 2025, with an adjusted net profit margin of 14.0%, reflecting a year-on-year increase of 0.4 percentage points and 1.3 percentage points, respectively. R&D expenses rose by 17.7% to 3.7 billion CNY, primarily due to increased AI investments and employee benefits [8] AI Business Development - The commercialization of Kuaishou's AI, known as Keling, progressed smoothly, generating over 300 million CNY in revenue in Q3 2025, a 20% increase from the previous quarter. The Keling 2.5 Turbo model topped global rankings in video and image generation shortly after its launch [8]

灯塔引领品质房企，精益求精笃行向上 建发国际集团(01908) 证券研究报告 房地产开发 / 公司深度研究报告 / 2025.11.24 投资评级:买入(首次) | 基本数据 | 2025-11-24 | | --- | --- | | 收盘价(元) | 16.95 | | 流通股本(亿股) | 22.40 | | 每股净资产(元) | 13.14 | | 总股本(亿股) | 22.40 | 最近 12 月市场表现 -19% -4% 12% 28% 44% 60% 建发国际集团 恒生指数 房地产开发 分析师 房诚琦 SAC 证书编号：S0160525090002 fangcq@ctsec.com 分析师 何裕佳 SAC 证书编号：S0160525090001 heyj@ctsec.com 分析师 陈思宇 SAC 证书编号：S0160525090008 chensy04@ctsec.com 相关报告 核心观点 盈利预测 | [币种Table_FinchinaSimple] (人民币) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | -- ...

证券研究报告 | 2025年11月24日 网易-S（09999.HK） 优于大市 递延收入增长 25%，经典游戏优异展现长期运营能力 收入同比上升 8%，销售费率环比继续所上升。25Q3，公司实现营收 284 亿 元，同比上升 8%。Non-GAAP 归母净利润 95 亿元，同比增长 27%；Non-GAAP 归母净利率 33.5%，同比提升 5pct。25Q3，公司综合毛利率 64.1%，同 比上升 1.2pct，网易云音乐毛利率同比提升 2.6pct。25Q3，公司总经 营费率为 36%，同比上升 0.2pct，环比上升 4pct。其中销售费率 15.7%， 同比上升 1pct，环比提升 3pct，游戏及相关增值服务市场推广支出增 加。我们预计 25Q4 销售费率环比略下降。 游戏：《梦幻西游》等经典游戏展现长期价值。2025Q3，在线游戏业务收 入为 228 亿元，同比增长 13%。递延收入表现良好，25Q3 网易递延收入 195 亿元，同比增长 25%。25Q3 老游戏表现优异，公司持续布局全球化。 1）多款经典游戏持续受到玩家欢迎，体现了网易游戏强劲的长线运营 能力。自三季度起，《梦幻西游》电脑版的 ...

Investment Rating - The report maintains a "Buy" rating for CSPC Pharmaceutical [8][14] Core Views - CSPC Pharmaceutical reported a revenue of RMB 19.89 billion for the first three quarters of 2025, a decrease of 12.3% year-on-year, with a net profit of RMB 3.51 billion, down 7.1% year-on-year. However, the third quarter showed signs of recovery with a revenue increase of 3.4% year-on-year to RMB 6.62 billion and a net profit increase of 27.2% year-on-year to RMB 964 million, aligning with expectations [5][10] - The company's gross margin decreased by 4.9 percentage points year-on-year to 65.6% in the first three quarters of 2025, with the sales contribution from finished drugs dropping from 82.3% to 77.7% [10][11] - The report highlights a significant decline in oncology product sales, which fell by 56.8% year-on-year to RMB 1.65 billion, representing only 10.7% of total finished drug sales [11] - CSPC has made progress in its innovative pipeline, with 28 key products in pivotal clinical trials and an increase in R&D expenses by 7.9% year-on-year to RMB 4.19 billion, reflecting a commitment to innovation [8][13] Financial Summary - For 2025, the company expects a revenue of RMB 26.785 billion, a decrease of 7.67% year-on-year, and a net profit of RMB 4.559 billion, with an EPS forecast adjusted down to RMB 0.40 [9][14] - The report projects a target price adjustment from HKD 12.7 to HKD 9.7, indicating a potential upside of 31% [14]

Investment Rating - The report maintains a "Buy" rating for CSPC Pharmaceutical [1][14] Core Views - The company reported a 12.3% year-on-year decline in revenue for the first three quarters of 2025, totaling RMB 19.89 billion, while net profit decreased by 7.1% to RMB 3.51 billion. However, in the third quarter, revenue grew by 3.4% year-on-year to RMB 6.62 billion, and net profit increased by 27.2% to RMB 964 million, aligning with expectations [4][10] - The gross margin decreased by 4.9 percentage points year-on-year to 65.6%, with the sales contribution from finished drugs dropping from 82.3% in the first three quarters of 2024 to 77.7% in 2025 [4][10] - The company has a robust pipeline with 28 key products in pivotal clinical trials and a significant increase in R&D expenses, which rose by 7.9% year-on-year to RMB 4.19 billion, representing 21.0% of revenue [7][13] Financial Performance - For the first three quarters of 2025, finished drug sales fell by 17.3% year-on-year to RMB 15.45 billion, but third-quarter sales returned to growth at RMB 5.20 billion, up 1.6% year-on-year [5][11] - The oncology product sales saw a significant decline of 56.8% year-on-year to RMB 1.65 billion, now representing 10.7% of total finished drug sales [5][11] - The API segment experienced a 22.3% year-on-year increase in vitamin C revenue to RMB 1.79 billion, while antibiotic API revenue slightly declined by 3.7% due to price drops [5][11] Pipeline Development - The company is advancing multiple trials for SYS6010 (EGFR ADC), which has received Fast Track Designation from the FDA and Breakthrough Therapy Designation from the NMPA, with data readouts expected in 2026 [6][12] - The innovative pipeline includes 28 products in phase II/III trials, nine in phase II, and approximately 40 in phase I, covering both oncology and non-oncology areas [7][13] Earnings Forecast - The earnings per share (EPS) forecast for 2025 has been adjusted down from RMB 0.46 to RMB 0.40, with target prices revised from HK$12.7 to HK$9.7, indicating a potential upside of 31% [14]

Investment Rating - The report maintains a "Buy" rating for MINISO, reflecting confidence in its growth potential and operational efficiency [4][6]. Core Insights - MINISO has demonstrated strong revenue growth, with a 28.2% year-on-year increase in revenue to 5.8 billion RMB in Q3 2025, alongside an adjusted net profit growth of 11.7% to 767 million RMB [1]. - The company is expanding its store network, adding 102 new stores in mainland China, bringing the total to 4,407, while overseas operations also saw a net increase of 117 stores, totaling 3,424 [2]. - The operational efficiency of overseas direct sales has improved, with a profit margin increase, particularly in strategic markets like North America and Europe [2]. Summary by Sections Domestic Operations - In Q3 2025, MINISO's domestic revenue reached 2.91 billion RMB, marking a 19.3% year-on-year increase, with same-store sales showing high single-digit growth [1]. - The company anticipates low double-digit same-store growth in mainland China by October 2025, projecting a full-year same-store growth in the mid-single digits [1]. Overseas Operations - The overseas business generated 2.31 billion RMB in revenue, a 27.7% increase year-on-year, accounting for 44.3% of total revenue [2]. - Same-store sales in overseas markets have shown improvement, particularly in strategic regions, contributing to the overall growth of the company [2]. Financial Performance - The adjusted operating profit for Q3 2025 was 1.02 billion RMB, reflecting a 14.8% year-on-year increase, with an adjusted operating profit margin of 17.6%, down 2.1 percentage points year-on-year [3]. - The gross profit for Q3 2025 was 2.59 billion RMB, with a gross margin of 44.7%, slightly down from the previous year [3]. Future Projections - Revenue projections for 2025-2027 are estimated at 21.3 billion RMB, 25.4 billion RMB, and 29.6 billion RMB respectively, with adjusted net profits expected to be 2.94 billion RMB, 3.48 billion RMB, and 4.08 billion RMB [4][5]. - The report indicates a continuous optimization of various business segments, products, and supply chains, supporting the company's growth trajectory [4].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 50.06, representing a potential upside of 30.36% from the current stock price of HKD 38.40 [3]. Core Insights - The company's Q3 2025 performance met expectations, with net revenue increasing by 14.0% year-on-year and 1.0% quarter-on-quarter, reaching HKD 12.16 billion, recovering to 95.7% of the same period in 2019 [3]. - The VIP gaming table turnover increased by 46.28% year-on-year and 16.6% quarter-on-quarter, while mass gaming revenue grew by 12.8% year-on-year and 7.4% quarter-on-quarter [3]. - The adjusted EBITDA for the group grew by 13.6% year-on-year but decreased by 6.4% quarter-on-quarter to HKD 3.34 billion, recovering to 81.3% of the same period in 2019 [3]. - The company holds a strong balance sheet with net cash of HKD 34.8 billion, the strongest in the industry [3]. Financial Summary - Total net revenue is projected to grow from HKD 35,683.6 million in 2023 to HKD 55,764.5 million by 2027, reflecting a compound annual growth rate (CAGR) of 8.5% [2][4]. - EBITDA is expected to increase from HKD 9,955.0 million in 2023 to HKD 16,439.8 million in 2027, with an EBITDA margin improving from 27.9% to 29.5% over the same period [2][4]. - Net profit is forecasted to rise from HKD 6,828.0 million in 2023 to HKD 12,317.4 million in 2027, indicating a CAGR of 9.6% [2][4]. - The company plans to maintain a dividend payout, with dividends per share expected to increase from HKD 0.5 in 2023 to HKD 1.6 in 2027, resulting in a dividend yield of 4.3% by 2027 [2][4]. Operational Highlights - The performance of "Galaxy Macau™" and the StarWorld Hotel showed a net revenue increase of 20% and a decrease of 6% year-on-year, respectively, with hotel occupancy rates at 98% and 99% [3]. - The company is progressing with the construction of the fourth phase of "Galaxy Macau™," expected to be completed in 2027, which will introduce several high-end hotel brands and a theater with 5,000 seats [3]. - The company hosted approximately 260 entertainment, sports, arts, and cultural events from January to September 2025, leading to a 41% year-on-year increase in visitor traffic to "Galaxy Macau™" [3].

曲公司 | 市场数据: | 2025 年 11 月 21 日 | | --- | --- | | 收盘价（港币） | 0.82 | | 恒生中国企业指数 | 8919.78 | | 52 周最高/最低 (港币) | 1.37/0.40 | | H 股市值（亿港币） | 244.98 | | 流通 H 股 (百万股) | 29,875.86 | | 汇率（港币/人民币） | 0.9106 | (01060) -IP 收入超一倍增长，演出业务多元探索 报告原因:有业绩公布需要点评 (维持) and of the see and the sere and the server the server the 传媒 2025 年 11 月 24 日 大蔓娱乐 一年内股价与基准指数对比走势: 7939 资料来源：Bloomberg 联系人 张淇元 A0230124080001 zhangqy@swsresearch.com 申万宏源研究微信服务号 相关研究 证券分析师 林起贤 A0230519060002 linqx@swsresearch.com 任梦妮 A0230521100005 renmn@swsresearch ...

Investment Rating - The report maintains a "Buy" rating for Kuaishou Technology [3][6]. Core Insights - Kuaishou's revenue for Q3 2025 reached 35.6 billion yuan, a year-on-year increase of 14.2%. The revenue from online marketing services, live streaming, and other services was 20.1 billion, 9.6 billion, and 5.9 billion yuan, respectively, with growth rates of 14.0%, 2.5%, and 41.3% [1]. - The company's operating profit for the quarter was 5.3 billion yuan, with an operating profit margin of approximately 14.9%. The non-GAAP net profit attributable to shareholders was 5.0 billion yuan, up 26.3% year-on-year, with a non-GAAP net profit margin of about 14.0% [1]. - E-commerce GMV grew robustly, increasing by 15.2% year-on-year to 385 billion yuan, with a healthy development in the average buyer structure and active user repurchase frequency [1][2]. - The AI models, such as OneRec and G4RL, have become new drivers for advertising revenue growth, contributing approximately 4%-5% to domestic online advertising revenue [2]. Financial Summary - The projected revenues for Kuaishou from 2025 to 2027 are 141.5 billion, 155.0 billion, and 167.0 billion yuan, representing year-on-year growth rates of 11%, 10%, and 8% respectively. Adjusted net profits are expected to be 20.5 billion, 24.8 billion, and 27.8 billion yuan, with growth rates of 16%, 21%, and 12% [3][5]. - The adjusted EPS for the same period is projected to be 4.8, 5.8, and 6.5 yuan, with a net asset return rate of 25.6%, 24.2%, and 21.8% respectively [5][12]. - The target price for Kuaishou is set at 94 HKD based on a 15x P/E ratio for 2026 estimates [3].

Investment Rating - The report maintains a "Strong Buy" rating for the company [3][6] Core Insights - The company reported Q3 revenue of 5.8 billion (+28.2% YoY) and adjusted net profit of 770 million (+11.7% YoY), with a net profit margin of 13.2% (-2.0 percentage points) [1][6] - Domestic revenue for the company's brand reached 2.91 billion (+19.3% YoY), while overseas revenue was 2.31 billion (+27.7% YoY). TOPTOY revenue surged to 570 million (+111.4% YoY) [1][6] - The company has a robust "1+3" moat strategy, combining a Chinese supply chain, global IP, global design, and global channels, which supports its domestic expansion and high growth in overseas markets [1][6] Financial Performance - The company expects significant revenue growth, with projected revenues of 13.84 billion, 16.99 billion, 21.21 billion, 25.13 billion, and 29.27 billion for 2023 to 2027, respectively, reflecting growth rates of 39%, 23%, 25%, 18%, and 17% [2][7] - Adjusted net profit is projected to grow from 2.39 billion in 2023 to 4.34 billion in 2027, with corresponding growth rates of 101%, 13%, 10%, 23%, and 18% [2][7] - The company’s earnings per share (EPS) is expected to increase from 1.90 in 2023 to 3.45 in 2027 [2][7] Domestic Market Performance - In Q3, the domestic brand revenue was 2.91 billion, with same-store sales showing high single-digit growth. The company anticipates low double-digit growth in same-store sales for Q4 [1][6] - The company added 102 new stores in Q3, bringing the total to 4,407 stores [1][6] International Market Performance - The overseas brand revenue reached 2.31 billion, with same-store sales showing low single-digit growth. The U.S. market saw revenue growth exceeding 65% [1][6] - The company opened 117 new stores overseas in Q3, with a total of 3,424 stores by the end of the quarter [1][6] TOPTOY Performance - TOPTOY brand revenue reached 570 million in Q3, with a same-store sales growth in the mid-single digits and a net increase of 14 stores, totaling 307 stores [1][6]